Pulmonry Embolism in Pregnancy ๐คฐ
Related Subjects:
| Pulmonary Embolism ๐ซ
| Pulmonary Embolism in Pregnancy๐ซ
| Assessing Breathlessness
| Deep Vein Thrombosis
| DVT/PE in pregnancy
| CTPA In PE
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a leading direct cause of maternal mortality in the UK. Pregnancy and the postpartum period are physiologically hypercoagulable states. Early recognition, appropriate investigation, and prompt anticoagulation are essential to prevent maternal morbidity and mortality.
๐ Epidemiology
- Incidence: ~1โ2 per 1000 pregnancies
- Risk is 5โ10ร higher than in non-pregnant women
- Highest risk: first 6 weeks postpartum
- Most antenatal DVTs occur in the left leg (iliac vein compression by gravid uterus)
๐งฌ Pathophysiology - Virchowโs Triad in Pregnancy
- Hypercoagulability:
- โ Clotting factors VII, VIII, X, fibrinogen
- โ Protein S
- Reduced fibrinolysis
- Venous Stasis:
- Uterine compression of pelvic veins
- Reduced venous return
- Endothelial Injury:
- Delivery and caesarean section
- Postpartum vascular trauma
โ ๏ธ Risk Factors
- Previous VTE
- Thrombophilia (Factor V Leiden, Prothrombin mutation, APS)
- Obesity
- Age >35 years
- Multiple pregnancy
- Immobility
- Caesarean section
- Sepsis
- Postpartum haemorrhage
- Severe hyperemesis
๐ฉบ Clinical Presentation
- New or worsening dyspnoea
- Pleuritic chest pain
- Tachycardia out of proportion to gestation
- Unilateral leg swelling/pain
- Syncope (concerning)
- Hypoxia
- Shock (massive PE)
Symptoms may overlap with normal pregnancy physiology - clinical suspicion must remain high.
๐งฎ Diagnostic Principles
Do NOT use Wells score or D-dimer alone to exclude PE in pregnancy. D-dimer rises physiologically during gestation.
๐ Diagnostic Pathway (NICE NG158 + RCOG aligned)
| Step |
Action |
| 1๏ธโฃ Suspected DVT |
If unilateral leg symptoms โ Bilateral compression ultrasound.
If DVT confirmed โ Treat as PE (no chest imaging required).
|
| 2๏ธโฃ Chest X-Ray |
Perform CXR in all suspected cases.
Used to guide imaging modality.
|
| 3๏ธโฃ Normal CXR |
Offer V/Q scan (lower breast radiation).
|
| 4๏ธโฃ Abnormal CXR |
Offer CTPA.
|
| 5๏ธโฃ Imaging Delayed |
Start treatment-dose LMWH immediately.
|
๐ฅ๏ธ Imaging Explained
- CXR: Usually normal; helps determine V/Q vs CTPA
- V/Q Scan: Detects ventilation-perfusion mismatch; preferred if CXR normal
- CTPA: Direct visualisation of clot; preferred if CXR abnormal
- Modern imaging delivers very low fetal radiation exposure. Maternal survival takes priority.
๐ Treatment
First-Line: Low Molecular Weight Heparin (LMWH)
- Enoxaparin: 1 mg/kg twice daily
- Dalteparin: 200 units/kg once daily (max 18,000 units)
- Adjust for renal impairment
- LMWH does not cross the placenta and is safe in pregnancy.
Duration
- Minimum 3 months total treatment
- Continue for at least 6 weeks postpartum
Avoid
- DOACs (Apixaban, Rivaroxaban)
- Warfarin (teratogenic in pregnancy)
๐จ Massive PE in Pregnancy
- Hypotension (SBP <90 mmHg) or shock
- Urgent senior and multidisciplinary input
- Consider thrombolysis in life-threatening cases
- Maternal survival takes precedence
๐ผ Postpartum Considerations
- Highest VTE risk: first 6 weeks postpartum
- Continue LMWH during this period
- Breastfeeding safe with LMWH and warfarin
- Avoid DOACs during breastfeeding
๐ Unprovoked PE in Pregnancy
- Screen for thrombophilia only if strong history or unusual presentation
- Plan thromboprophylaxis in future pregnancies
๐ง Clinical Pearls
- Do not rely on D-dimer to exclude PE
- Ultrasound first if DVT symptoms
- CXR guides imaging choice
- LMWH is the cornerstone of treatment
- Continue anticoagulation postpartum
- Massive PE requires urgent senior involvement